Frontiers Innovation Forum on Peptide and Nucleic Acid Drugs
2024year5month10 - 11Date, hosted by Pharmaceutical KnowledgePNTThe Frontier Innovation Forum on Peptide and Nucleic Acid Drugs was successfully held in Shanghai. This conference focused on peptides, small nucleic acids,mRNAHot topics related to drug research and development, process development, quality research, commercial production, etc., are covered by four special forums. Invitations are extended to60+Experts, scholars, research backbones, and enterprise representatives from related fields across the country exchanged experiences to jointly discuss the future development of peptide and nucleic acid drugs.
Frost & SullivanFrost & SullivanLi Qian, consulting director of the Life Sciences Business Unit in Greater China at Frost & Sullivan, was invited to attend the event and delivered a presentation onmRNADelivered a speech on "The Current Situation and Trends of the Pharmaceutical Market".
Consulting Director, Life Sciences Business Unit, Frost & Sullivan Greater China Region Li Qian
Li Qian pointed out that looking back at the exploration of disease treatment, people have never stopped pursuing higher safety and better patient outcomes.mRNADrug research and development is highly efficient, with a simple production process and the ability to expand into diverse disease areas. It represents a highly promising innovative therapy and is a current research hotspot in the biopharmaceutical industry. As of now, there are8modelmRNAVaccine approved for marketing, domestic manufacturersmRNAVaccines have also made significant progress. Driven by factors such as breakthroughs in key technologies, commercial success, multi-party R&D cooperation, and policy support, the futuremRNAThe pharmaceutical market has tremendous potential.
Source: Analysis by Frost & Sullivan
According to a study by Frost & Sullivan, as of2024year1months, globally162modelmRNAThe drug is in the clinical stage, mainly comprisingmRNAVaccines, accounting for approximately70%, and mostmRNAThe drug is still inIperiod andIIPhase clinical stage. In terms of therapeutic areas, global clinical research is ongoingmRNAThe main indications for the drug pipeline are infectious diseases and tumors, accounting for more than half of all pipelines.90%Currently, the indications with relatively rapid progress include melanoma, non-small cell lung cancer, colorectal cancer, and head and neck cancer. In addition, glioma, pancreatic cancer, and gynecological tumors are also included.mRNADrug research and development. Li Qian said,mRNAThe drug production process is simple and fast, and the upstream and downstream industries of the supply chain are becoming increasingly mature. In the future, as the R&D system is gradually improved and technological applications mature,mRNAThe pharmaceutical market in the therapeutic field will continue to expand, with the industry achieving synchronous development and realizing commercial cooperation.
More exciting moments from the event arena
About Frost & Sullivan's Life Sciences Practice
The Life Sciences Practice of Frost & Sullivan has professional analytical capabilities and extensive project experience in the field of life sciences. Leveraging Frost & Sullivan's global think tank resources and cross-industry business development platform in Greater China, the Life Sciences Practice has unique core advantages in investment and financing services for the life sciences industry. The Life Sciences Practice has a wide range of corporate clients in China and in the past20In the year, a vast customer network was established, accumulating a wealth of project experience in various subfields of life sciences.
Project types include Knowledge Center projects (in-depth content, promotional activities).Pre-IPO financingprojectDCF modelValuation, Business Plan Services),IPO listingWe provide listed projects (industry consulting, clinical audits, fundraising and investment writing), market research, market value management, and strategic consulting. We also cooperate with well-known domestic and international information platforms and investment and financing institutions to offer one-stop solutions for enterprises in specialized sub-sectors such as pharmaceuticals and medical devices. Our services have received wide attention from investors.
